Bmnr stock price forecast gains traction after improved

BMNR stock price forecast gains traction after improved liquidity readings; implied upside potential strengthens short-term bullish case. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reaffirmed its 2027 revenue objective of about $4 billion and increased its full-year 2024 outlook due to the high demand for enzyme treatments and VOXZOGO. On September 15, 2025, BitMine Immersion Technologies announced its crypto and cash holdings totaling $10.8 billion, including over 2.151 million Ethereum tokens, making it the largest Ethereum treasury globally. The company, supported by prominent institutional investors, aims to acquire 5% of Ethereum and is ranked as the 28th most traded stock in the US, with a daily trading volume of $2 billion. BitMine’s strategy is driven by the convergence of Wall Street and AI onto the blockchain, which is expected to transform the financial system, with Ethereum playing a central role in this evolution. Trader chatter around BMNR points to bullish sentiment; forecast models highlight a near-term test of previous highs if support levels hold.